Sally Beauty (SBH) Reports Q3 Earnings: What Key Metrics Have to Say

Sally Beauty (SBH) reported Q3 2025 diluted EPS of $0.51, significantly exceeding the $0.42 consensus, and revenue of $933.31 million, which slightly beat estimates despite a 1% year-over-year decline. However, key operational metrics revealed weakness, with consolidated comparable sales decreasing by 1%, missing the 0.1% analyst estimate, primarily driven by a 1.8% decline in the Sally Beauty Supply segment. This mixed performance, characterized by an earnings beat but underlying sales deceleration, suggests ongoing organic growth challenges, reinforced by the stock's recent underperformance against the S&P 500 and a Zacks Rank #4 (Sell) indicating a cautious near-term outlook.

Analysis

Sally Beauty's (SBH) third-quarter 2025 results present a mixed financial picture, where a significant earnings beat masks underlying operational weakness. The company reported EPS of $0.51, a 21.43% positive surprise against the consensus estimate of $0.42 and an increase from $0.45 in the prior-year quarter. However, this bottom-line strength is contrasted by a 1% year-over-year revenue decline to $933.31 million and, more critically, a miss on key growth metrics. Consolidated comparable sales fell 1%, missing the analyst estimate of a 0.1% gain. This decline was driven almost entirely by the core Sally Beauty Supply segment, which posted a substantial 1.8% drop in comparable sales, starkly underperforming the expected 1% growth. In contrast, the Beauty Systems Group segment remained relatively stable with 0.2% comparable sales growth, nearly meeting its 0.3% estimate. This operational softness, coupled with the stock's recent underperformance against the S&P 500 (+0.5% vs +1.0% for the S&P) and a Zacks Rank #4 (Sell), suggests that challenges in organic growth and consumer demand are outweighing the positive earnings surprise.

Key Decisions for Investors

• Investors should look past the headline EPS beat of 21.43% and focus on the deteriorating top-line fundamentals, particularly the -1.0% consolidated comparable sales miss.
• The diverging performance between the struggling Sally Beauty Supply segment (-1.8% comp sales) and the stable Beauty Systems Group (+0.2% comp sales) is a key risk factor to monitor for further degradation.
• Given the negative underlying sales trends, recent market underperformance, and a formal 'Sell' rating from Zacks, it may be prudent to remain on the sidelines or consider reducing exposure until there are clear signs of a turnaround in comparable sales growth.